Real-World Evidence: Advice, Principles And Examples Emerge From FDA
Executive Summary
Biopharma sponsors are eagerly awaiting guidance on how to apply 'real-world evidence' to drug development and regulatory decisions. Recent workshops provide some clues about what is likely to be included in the first drafts.
You may also be interested in...
US FDA Wants More Examples Of Real-World Data Use
CDER Director Woodcock says for regulatory purposes, using real-world data likely will remain a case-by-case decision.
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Commissioner tells House hearing that agency study found troubling drop in innovative competition; clinical trial reform, including encouraging surrogate markers, could speed development of products that may create pricing pressure on brands.
Real World Evidence Benefits, Limits Explored In US FDA Demonstrations
FDA's Jacqueline Corrigan-Curay lists three demonstrations now underway that are aimed at looking at different aspects of generating real world evidence and may inform the agency's evaluation of the data and methods.